- Home
- OMER vs EVAC Comparison
OMER vs EVAC Comparison
Compare OMER & EVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMER | EVAC |
|---|---|---|
| Founded | 1994 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.9M | 584.5M |
| IPO Year | 2009 | 2025 |
Fundamental Metrics
Financial Performance| Metric | OMER | EVAC |
|---|---|---|
| Price | $12.52 | $10.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $32.50 | N/A |
| AVG Volume (30 Days) | ★ 4.4M | 40.2K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.95 | $9.90 |
| 52 Week High | $17.65 | $10.17 |
Technical Indicators
Market Signals| Indicator | OMER | EVAC |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | N/A |
| Support Level | $11.85 | N/A |
| Resistance Level | $16.14 | N/A |
| Average True Range (ATR) | 1.62 | 0.00 |
| MACD | -0.37 | 0.00 |
| Stochastic Oscillator | 43.31 | 0.00 |
Price Performance
Historical ComparisonAbout OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About EVAC EQV Ventures Acquisition Corp. II Class A Ordinary Shares
EQV Ventures Acquisition Corp II is a blank check company.